Results 1 to 10 of about 302 (114)
The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
Frontiers in Molecular Biosciences, 2020 The emergence and global impact of COVID-19 has focused the scientific and medical community on the pivotal influential role of respiratory viruses as causes of severe pneumonia, on the understanding of the underlying pathomechanisms, and on potential ...
Ludwig Aigner +12 more
doaj +3 more sources
Role of Antileukotrienes In Prevention of Recurrence of Nasal Polyps [PDF]
Zagazig University Medical Journal, 2023 Background: Nasal polyps are common in patients with chro nic rhinosinusitis, yet, to date, little is known about the pathophysiology of nasal polyp formation. This study aimed to determine the effect of montelukast (a leukotriene receptor antagonist) as
Samir Sorour +3 more
doaj +1 more source
Leukotriene Receptor Antagonists [PDF]
Seminars in Respiratory and Critical Care Medicine, 2002 In the past decade, heightened emphasis has been placed on the importance of inflammation in the pathogenesis of asthma. Although corticosteroids have remained the primary anti-inflammatory agents in the management of the persistent asthmatic, new classes of drugs have recently been added.
Marzena E, Krawiec, Nizar J, Jarjour
openaire +2 more sources
Leukotrienes, leukotriene receptor antagonists, and rhinitis [PDF]
Allergy, 2000 A series of clinical studies have shown the ef®cacy of leukotriene (LT) receptor antagonists (LTRAs) in the treatment of bronchial asthma (1±6). LTRAs relieve bronchospasm, prevent exercise-induced asthma, and reduce bronchial hyperresponsiveness.
N, Mygind, R, Dahl, H, Bisgaard
openaire +2 more sources
Leukotriene receptor antagonists for eczema [PDF]
Cochrane Database of Systematic Reviews, 2018 Eczema is a common, chronic, inflammatory skin condition that is frequently associated with atopic conditions, including asthma. Leukotriene receptor antagonists (LTRAs) have a corticosteroid-sparing role in asthma, but their role in eczema remains controversial.
Leila, Ferguson +6 more
openaire +2 more sources
Bengal Journal of Otolaryngology and Head Neck Surgery, 2017 Introduction Pharmacologic treatment options for allergic rhinitis include intranasal corticosteroids, oral and topical antihistamines, decongestants, intranasal cromolyn, intranasal anticholinergics and leukotriene receptor antagonists.
Gurpreet Kaur +2 more
doaj +3 more sources
Expert opinion on montelukast and acebrophylline combination in the management of asthma
Indian Journal of Allergy Asthma and Immunology, 2021 Asthma control is highly inadequate in India, with worse outcomes and poor adherence to inhaled corticosteroids (ICSs). As per the Global Initiative for Asthma guidelines, leukotriene receptor antagonist (LTRA) can be added when a low-to-moderate dose of
N H Krishna +5 more
doaj +1 more source
Cysteinyl leukotriene receptor 1 is dispensable for osteoclast differentiation and bone resorption.
PLoS ONE, 2022 Cysteinyl leukotriene receptor 1 (CysLTR1) is a G protein-coupled receptor for the inflammatory lipid mediators cysteinyl leukotrienes, which are involved in smooth muscle constriction, vascular permeability, and macrophage chemokine release. The Cysltr1
Hirofumi Fujita +8 more
doaj +1 more source
Journal of Pharmacological Sciences, 2010 We investigated pharmacological characteristics of the itch-associated response to chronic dermatitis induced by 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone) repeated application in mice.
Yukihito Tsukumo +2 more
doaj +1 more source
Journal of Pharmacological Sciences, 2007 This study investigated endogenous mediators involved in mosquito allergy-associated itching in mice. An intradermal injection of an extract of mosquito salivary gland elicited marked scratching in sensitized mice.
Yasushi Kuraishi +6 more
doaj +1 more source